Byron Donalds
Byron Donalds (R-FL) bought $1K-$15K of $FCNCA (First Citizens BancShares, Inc. - Class A Common Stock (FCNCA) [ST]) on Jan 21, 2025, part of 13 transactions in this filing (7 buys, 6 sells).
HillSignal flagged 2 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Suspicious Timing Detected
2 flagsRep. Donalds sold $1K-$15K in $MRK on January 16, 2025 — 7 days after the 'Skinny Labels, Big Savings Act' (S.43) was introduced on Jan 9, a bill that could increase generic competition and pressure Merck's drug profits.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $FCNCA | First Citizens BancShares, Inc. - Class A Common Stock (FCNCA) [ST] | $1K-$15K | — | — | — | Jan 21, 2025 |
| BUY | $FCNCA | First Citizens BancShares, Inc. - Class A Common Stock (FCNCA) [ST] | $1K-$15K | — | — | — | Jan 21, 2025 |
| BUY | $FCNCA | First Citizens BancShares, Inc. - Class A Common Stock (FCNCA) [ST] | $1K-$15K | — | — | — | Jan 16, 2025 |
| BUY | $GDDY | GoDaddy Inc. Class A Common Stock (GDDY) [ST] | $1K-$15K | — | $85.30 | — | Jan 16, 2025 |
| BUY | $GDDY | GoDaddy Inc. Class A Common Stock (GDDY) [ST] | $1K-$15K | — | $85.30 | — | Jan 16, 2025 |
| BUY | $GDDY | GoDaddy Inc. Class A Common Stock (GDDY) [ST] | $1K-$15K | — | $85.30 | — | Jan 21, 2025 |
| BUY | $GDDY | GoDaddy Inc. Class A Common Stock (GDDY) [ST] | $1K-$15K | — | $85.30 | — | Jan 21, 2025 |
| SELL | $MRK | Merck & Company, Inc. Common Stock (MRK) [ST] | $1K-$15K | $100.70 | — | — | Jan 16, 2025 |
| SELL | $MRK | Merck & Company, Inc. Common Stock (MRK) [ST] | $1K-$15K | $100.70 | — | — | Jan 16, 2025 |
| PARTIAL SELL | $RLI | RLI Corp. Common Stock (RLI) [ST] | $1K-$15K | $77.83 | — | — | Jan 16, 2025 |
Connected Legislative Activity
7 signalsThese bills and contracts share tickers or sectors with this filing's trades.
ABC Safe Drug Act
The ABC Safe Drug Act (S. 1407) is in early legislative stages, having been referred to the Senate Finance Committee. It phases in restrictions on federal health programs purchasing drugs with Chinese active ingredients by 2030 and provides temporary tax incentives for domestic pharmaceutical manufacturing. Major pharma stocks ($PFE, $MRK, $JNJ, $LLY, $AMGN) show mixed but broadly negative 7-day changes, reflecting sector headwinds rather than this nascent bill. No market-moving impact is imminent.
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.
HR1492 retroactively extends the Medicare price negotiation safe harbor for small-molecule drugs from 7 to 11 years, matching biologics. This shields billions in revenue for major pharma companies, particularly pure-play small-molecule firms like Vertex and large players with top-selling Part D drugs like Pfizer, Bristol-Myers Squibb, and Gilead. The bill is early-stage with 67 cosponsors and a Republican sponsor, giving it moderate momentum.
Providing Veterans Essential Medications Act
HR1970 (Providing Veterans Essential Medications Act) is in early legislative stages, having been referred to the House Veterans' Affairs subcommittee. The bill mandates VA reimbursement for high-cost medications dispensed to veterans in State nursing homes, but authorizes no specific funding and remains months from passage. Real market data shows CVS up 16% in 30 days while CAH is down 10%, reflecting broader distribution-sector dynamics rather than this early-stage bill.
Medicare for All Act
Medicare for All Act (HR3069) would eliminate private health insurance, replacing it with a single-payer federal program. The bill is in early legislative stages (referred to 7 committees, 114 cosponsors, all Democrats). Recent real market data shows private insurers rallied 20-70% over the past 30 days on unrelated factors (likely earnings or regulatory clarity), not legislative risk. A structural existential threat exists for managed care companies if this bill advanced to law — but current legislative probability near zero given Republican House control and early-stage procedural status.
EPIC Act of 2025
The EPIC Act of 2025 would extend small-molecule drug exclusivity before Medicare price negotiation from 7 to 11 years for drugs approved after 2028. Despite sector-wide 30-day declines ($MRK -7.18%, $GSK -5.02%, $PFE -4.24%), the bill's early-stage status (referred to Senate Finance Committee) and long legislative path mean no near-term revenue impact. The structural beneficiary is clear: small-molecule-focused pharma pipelines gain 4 additional years of un-negotiated pricing.
Access to Pediatric Technologies Act of 2025
HR1931, the Access to Pediatric Technologies Act, is an early-stage House bill that would require CMS to establish Medicare payment methodologies for qualifying pediatric devices and drugs upon manufacturer request. The bill is referred to two committees with no further action in over a year. It authorizes no direct funding - it creates a regulatory pathway. For med-tech and pharma companies with pediatric product lines (JNJ, ABT, MRK, PFE), the bill is directionally positive but procedurally distant from becoming law.
Skinny Labels, Big Savings Act
The Skinny Labels, Big Savings Act (S.43) creates a statutory safe harbor protecting generic drug manufacturers from patent infringement lawsuits when they seek FDA approval for and market 'skinny label' generics. The bill is in early legislative stages (referred to Senate Judiciary Committee, January 2025). If enacted, it structurally favors generic manufacturers like Teva ($TEVA) and Viatris ($VTRS) by eliminating litigation risk, while negatively impacting brand-name drug companies whose multi-use patents will no longer block generic entry. Teva's stock has rallied 13.36% in 7 days and 24.8% in 30 days; Viatris gained 1.49% (7-day) and 15.51% (30-day), reflecting early market pricing of this regulatory catalyst.
Other Filings by Byron Donalds
Free — no credit card
Get the next Donalds trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.